Term Effective:
Full Title: Advanced Cardiac Life Support (limit to 50 characters including spaces) If this is a variable unit course, then the relationship between units and any difference in expected SLO’s should be explained. Student Learning Outcomes: (Enter the SLO’s in an outline format. Use the Ctrl + Tab keys to indent for subtopics.)
At the conclusion of this course students will be able to demonstrate mastery of the following topics
necessary for certification in ACLS:
A. For all ACLS devices and procedures, students must know:
1. Indications (knowledge of when to use and why)
2. Precautions (knowledge of when not to use each and why)
3. Proper use (hands on practice)
B. For pharmacological agents, students must know:
1. Why an agent is used (actions)
2. When to use an agent (indications)
3. How to use an agent (dosing)
4. What to watch out for (precautions)
C. Airway management and endotracheal intubation, including:
1. Noninvasive airway techniques and devices (hands on practice)
2. Techniques to administer oxygen (hands on practice)
3. Endotracheal intubation (hands on practice
D. Recognition and therapy of the major ACLS emergency conditions:
1. Universal algorithm
2. Ventricular fibrillation/pulseless ventricular tachycardia
3. Pulseless electrical activity (PEA)
4. Asystole
5. Bradycardia
6. Tachycardias
7. Acute myocardial infarction (MI)
8. Hypotension/shock/acute pulmonary edema
E. Electrical therapy, including:
1. Defibrillation with automated external defibrillators
2. Defibrillation with conventional defibrillators
Course Level Student Learning Outcomes
3. Attachment of defibrillators as a cardiac monitor 4. Electrical cardioversion with conventional defibrillators 5. Transcutaneous pacemakers F. Intravenous and invasive therapeutic and; monitoring techniques, including: 1. Peripheral IV lines 2. Central IV lines 3. Pericardiocentesis 4. Thoracentesis for tension pneumothorax G. Recognition of the following rhythms 1. Lethal rhythms 2. Nonlethal arrhythmias H. ACLS cardiovascular pharmacology, including the why, when, how, and precautions of the following agents: 1. electricity, oxygen, epinephrine, lidocaine, bretylium, magnesium sulfate, procainamide, socium bicarbonate, atropine, dopamine, isoproterol, vagal maneuvers, adenosine, verapamil, biltiazem, beta blocker, nitroglycerin, nitroprusside, dobutamine, morphine sulfate, furosemide, and a thrombolytic agent I. Early management (first 30 minutes) of the following sepcial resuscitation; situations: 1. Stroke 2. Hypothermia 3. Drowning and near drowning 4. Cardiac arrest associated with trauma 5. Electrocution and lightning strike 6. Cardiac arrest of the pregnant patient 7. Possible drug overdose J. Megacode leadership and participation including: 1. Knowledge and skill to manage the core Megacode scenario: the first 10 minutes of an adult VF cardiac arrest 2. The core Megacode scenario covers the following areas: a) Universal algorithm (for pulseless patient) b) Basic adult CPR (primary ABCD survey) c) VF/VT algorithm d) Appropriate use of the secondary ABCD survey e) Acceptable noninvasive airway management techniques f) Endotracheal intubation (only if professional role requires) g) IV techniques (peripheral line only) h) Defibrillation with AEDs and conventional defibrillators i) Use of pharmacologic agents: epinephrine, lidocaine, bretylium, procainamide, sodium bicarbonate, and magnesium sulfate

Course Level Student Learning Outcomes


Microsoft word - news letter 4.doc

Dear friends of Bezaleel. How time flies! Sometimes our days resemble some attempt at controlled chaos with unexpected illness throwing carefully planned days to the wind. Nevertheless, God is in control, He is good and expresses His love and provision for us in a constant and faithful way. As far as some of our children are concerned a lot has happened since we last wrote to you, so let me begin

China’s Hisun Files IND For Cholesterol-lowering Drug In U.S. Hisun, best known for a proposed JV with Pfizer on branded generics, is looking to move up the value chain into R&D. SHANGHAI – One of China’s leading active pharma-latory consulting for the IND preparation (CMC, phar-ceutical ingredient and finished product manufacturers macology/toxicology and clinical development plan/

© 2008-2018 Medical News